Abstract : CLABSI rates in PHO and HSCT units have been decreasing, yet the peril of causing infection to patients exists. Product information review of a new disinfectant port protector cap promises a potential of further reducing CLABSI risk when utilized. Method and Materials The study conducted covered 23 beds at PHO and HSCT units in a tertiary referral hospital in Dammam, Saudi Arabia, which started in January 2017 until June 2019. The participants were pediatric patients younger than 16 years old. The new disinfectant port protector cap was introduced to disinfect CVC IV needleless connectors including IV administration ports beginning of April 2018. To ascertain the impact of this product, it was integrated into the existing CLABSI prevention bundle. Nurse's compliance in its use was likewise monitored. Results CLABSI rates before product utilization (15 months) were compared with rates after the product was used which ran also for (15 months). CLABSI rates per 1000 central line days showed the following data: January 2017 to March 2018 (before implementation): mean-SD was 2.81(21 cases)-SD 2.15). April 2018 to June 2019 (after implementation): mean-SD was 0.55(4 cases)-0.95 SD). Mean difference was 2.26, and a 95% confidence interval of (1.21 to 3.30) with t (14) = 4.66, p = 0.000. There was an 80% reduction in CLABSI rates. Nurse's compliance using the cap showed a low of 85% to a high of 100% with an average of 96%. Conclusion The study significantly showed that the use of a disinfectant port protector cap effectively contributed to a lower incidence of CLABSI rates. It likewise improved nurse’s compliance to cap use. Recommendations It cannot be overemphasized the importance of making a disinfectant port protector cap an essential element of the central line maintenance bundle to attain an acceptably low CLABSI rate. Keywords: Catheter-Related Infections; Central Line-Associated Bloodstream Infections; Central Venous Catheters; Curos® Cap; Disinfection Port Protector Cap.